Sildenafil Teva
From £3.99
Clinical Trial Evidence for Sildenafil 50mg
Landmark Clinical Studies
Sildenafil's development began with pivotal phase III clinical trials involving thousands of men with erectile dysfunction. These randomised, double-blind, placebo-controlled studies established the foundation for regulatory approval. Research consistently demonstrated that sildenafil 50mg produced statistically significant improvements in erectile function compared to placebo across multiple assessment scales.
Efficacy Across Patient Populations
Clinical data reveals sildenafil's effectiveness across diverse populations. Studies in men with diabetes mellitus showed success rates of approximately 60%, while research in post-prostatectomy patients demonstrated improvements in 40-50% of participants. Broader population studies indicate overall success rates between 60-85%, with 50mg serving as the recommended starting dose for most patients. The International Index of Erectile Function (IIEF) scores showed meaningful improvements across treatment groups.
Dose-Response Research
Clinical trials specifically examining sildenafil 50mg versus other doses provide valuable insights. Research indicates that 50mg offers an optimal balance between efficacy and tolerability for most men. Studies show that while 100mg may provide marginally better results for some patients, 50mg produces satisfactory outcomes with fewer adverse events. Approximately 70% of men find 50mg effective, making it the standard starting dose recommended by healthcare professionals.
Safety Profile Evidence
Extensive safety data from clinical trials demonstrates sildenafil's generally favourable tolerability profile. Common side effects reported in studies include headache (16%), facial flushing (10%), and dyspepsia (7%). Most adverse events were mild to moderate and transient. Serious cardiovascular events were rare in clinical trials, though careful screening excluded high-risk patients. Long-term studies spanning several years confirm the safety profile remains consistent with continued use.
Real-World Evidence
Post-marketing surveillance and real-world studies complement clinical trial data. Research published in peer-reviewed journals continues to support sildenafil's effectiveness in routine clinical practice. Studies examining patient satisfaction rates consistently report high levels of treatment satisfaction, with many men continuing therapy long-term. Healthcare providers can offer both generic sildenafil and branded Viagra, allowing patients to choose based on their preferences and clinical assessment outcomes.
Current Research Developments
Ongoing research continues to expand understanding of sildenafil's mechanisms and applications. Recent studies examine its use in specific populations, optimal timing strategies, and potential combination approaches. Clinical research also investigates factors that may predict treatment response, helping healthcare providers personalise therapy recommendations. This evolving evidence base ensures treatment approaches remain current with latest scientific understanding.
